Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06892431 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

StatusNot Yet Recruiting
PhasePhase 2
Started2025-04-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 25, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-03-23
Study Status, Eligibility v1
Eligibility criteria+7 characters
Inclusion Criteria: 1. Able to understand and voluntarily sign the written ICF; 2. Aged 18-75 years old (inclusive), male or female; 3. Patients with nasopharyngeal cancer who have experienced tr [...] motherapy (including at least one line containing platinum); 4. According to RECIST v1.1, there is at least one measurable [...] herapy or has shown definite progression after radiotherapy; 5. ECOG PS score of 0-1; 6. Estimated lifespan of at least 3 months; 7. Have adequate organ function, laboratory test meets the fol [...] hematopoietic stimulating factor treatment within 14 days):(1)Hematology: a. Absolut [...] [...]
2025-03-21
Original filing
This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with recurrent/metastatic nasopharyngeal cancer who have failed at least two prior lines of treatment.
Trial Details
NCT Number NCT06892431
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
Enrollment 150 participants
Start Date 2025-04-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-25